prof. MUDr. Jiří Mayer, CSc.
Department head, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 3643, 3603 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 1627
2024
-
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Annals of hematology, year: 2024, volume: 103, edition: 7, DOI
-
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drug
Leukemia, year: 2024, volume: 38, edition: 8, DOI
-
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
Leukemia, year: 2024, volume: 38, edition: 2, DOI
-
VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).
Year: 2024, type: Conference abstract
-
VEXAS syndrom - nově popsané autoinflamatorní onemocnění s hematologickými symptomy. Popis případu a přehled literatury
Transfuze a hematologie dnes, year: 2024, volume: 30, edition: 2, DOI
-
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Leukemia, year: 2024, volume: 38, edition: 4, DOI
2023
-
Acute myeloid leukemia suppression by palbociclib and ponatinib in patient-derived xenograft.
Year: 2023, type: Conference abstract
-
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
Blood Cancer Journal, year: 2023, volume: 13, edition: 1, DOI
-
AML engraftment in humanized ossicles is not governed by biomaterial selection.
Year: 2023, type: Conference abstract
-
Analysis of factors influencing the decision to stop TKI treatment in CML patients in deep molecular response
Year: 2023, type: Conference abstract